TNF Receptor Inhibitor

Umckalin (Standard) is the analytical standard of Umckalin (HY-N8712). Umckalin is Coumarin (HY-N0709) derivative that exhibits anti-inflammatory properties. Umckalin reduces phosphorylation of p38 MAPK, JNK, and ERK, lowers TNF-α, IL-6, IL-1β, NO, and PGE₂ production. Umckalin can be used for the research of chronic inflammatory diseases.

2-Hydroxy-5-(2-nitrovinyl) benzoic acid (SANA) is an orally active pleiotropic anti-inflammatory metabolic modulator. 2-Hydroxy-5-(2-nitrovinyl) benzoic acid inhibits NF-κB, activates Nrf2/Keap1 and AMPK, suppresses inflammasome activity, induces thermogenesis, reverses insulin resistance and alleviates skin graft rejection. 2-Hydroxy-5-(2-nitrovinyl) benzoic acid can be used in research related to obesity, glucose intolerance, skin graft rejection and insulin resistance.

SPD304 (Standard) is the analytical standard of SPD304 (HY-111255). This product is intended for research and analytical applications. SPD304 is a selective TNF-α inhibitor, which promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor. SPD304 has an IC₅₀ of 22 μM for inhibiting in vitro TNF receptor 1 (TNFR1) binding to TNF-α.

Mouse Tnf ASO is an antisense oligonucleotide (ASO) that targets the expression of mouse TNF-α. Mouse Tnf ASO reduces the tissue levels of various pro-inflammatory cytokines, Th1 cytokines and Th17 cytokines. Mouse Tnf ASO improves the clinical and histopathological severity of experimental colitis, including alleviating weight loss, diarrhea and intestinal protein loss. Mouse Tnf ASO can be delivered to activated colonic macrophages in mice via galactosylated low-molecular-weight chitosan nanocomplexes, with higher delivery efficiency compared to naked ASO. Mouse Tnf ASO can be used in the research of Crohn's disease.

Hispidol (Standard) is the analytical standard of Hispidol. This product is intended for research and analytical applications. Hispidol ((Z)-Hispidol) is a potential therapeutic for inflammatory bowel disease; inhibits TNF-α induced adhesion of monocytes to colon epithelial cells with an IC50 of 0.50 μM.

Myristoyllysophosphatidylcholine is a NLRP3 inflammasome inhibitor with multiple activities including anti-inflammatory and antioxidant effects. Myristoyllysophosphatidylcholine inhibits LPS-induced NLRP3 inflammasome activation, reduces pro-inflammatory cytokine secretion, decreases ROS and MDA levels, alleviates lung tissue and cell damage, and mediates apoptosis. Myristoyllysophosphatidylcholine serves as a myristate donor for myristoylation of the Glucose-6-Phosphate Isomerase (GPI) anchor in Trypanosoma brucei and undergoes hydrolysis. Myristoyllysophosphatidylcholine acts as a biomarker for the severity of community-acquired pneumonia. Myristoyllysophosphatidylcholine can be used in research related to diseases such as community-acquired pneumonia and acute lung injury.

Schisantherin B (Gomisin-B) (Standard) is the analytical standard of Schisantherin B. This product is intended for research and analytical applications. Schisantherin B is a lignan compound and one of the active components of Schisandra chinensis. Schisantherin B activates the PI3K/AKT signaling pathway, restores the activity of GSK3β, and reduces the hyperphosphorylation of tau protein in hippocampal and cerebral cortical tissues. Schisantherin B upregulates the level of GLT-1, decreases the expression of pro-inflammatory cytokines TNF-α/IL-1β/IL-6, upregulates the expression of IL-10, and inhibits cell apoptosis. Schisantherin B is applicable to the research of spinal cord injury, Alzheimer's disease and depression.

GYY4137 (Standard) is the analytical standard of GYY4137 (HY-107632). This product is intended for research and analytical applications. GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocK_ing the STAT3 pathway, demonstrating potent anticancer activity.

ST-899 is a novel platelet-activating factor (PAF) receptor antagonist. ST-899 can significantly reduce the mortality of mice with endotoxin (LPS)-induced shock. ST-899 can significantly inhibit the increase in serum tumor necrosis factor (TNF) levels induced by LPS, but has no effect on interleukin-6 (IL-6). The regulatory mechanism of ST-899 is to block the positive feedback loop between PAF and TNF, thereby reducing the inflammatory response. ST-899 can be used to study inflammatory diseases such as septic shock.

Aspartyl-alanyl-diketopiperazine (DA-DKP) (Standard) is the analytical standard of Aspartyl-alanyl-diketopiperazine (HY-107091). This product is intended for research and analytical applications. Aspartyl-alanyl-diketopiperazine is an immunomodulatory molecule and anti-inflammatory agent. Aspartyl-alanyl-diketopiperazine increases the level of active Rap1 in activated human T lymphocytes and reduces the phosphorylation levels of Ras, ATF-2, c-jun, MEK1, MEKK1, ERK1, JNK1,2,3, p38MAPK and MEF-2. Aspartyl-alanyl-diketopiperazine inhibits the production of pro-inflammatory cytokines, including the levels of IFN-γ and TNF-α. Aspartyl-alanyl-diketopiperazine can be used in studies of inflammatory immune responses.

KR-33493 (Standard) is the analytical standard of KR-33493 (HY-100755). This product is intended for research and analytical applications. KR-33493 is a potent inhibitor of Fas-mediated cell death (FAF1).

Nomilin (Standard) is the analytical standard of Nomilin. This product is intended for research and analytical applications. Nomilin is a limonoid compound obtained from the extracts of citrus fruits. Nomilin is an anti-obesity and anti-hyperglycemic agent .

SPD304 dihydrochloride (Standard) is the analytical standard of SPD304 (dihydrochloride) (HY-111255A). This product is intended for research and analytical applications. SPD304 dihydrochloride is a selective TNF-α inhibitor, which promotes dissociation of TNF trimers and therefore blocks the interaction of TNF and its receptor. SPD304 has an IC₅₀ of 22 μM for inhibiting in vitro TNF receptor 1 (TNFR1) binding to TNF-α.

Roburic acid (Standard) is the analytical standard of Roburic acid. This product is intended for research and analytical applications. Roburic acid acts as an anti-inflammatory, anti-tumor and osteoclastogenesis inhibitor, with a K_i of 7.066 μM against human TNF, an IC₅₀ of 9 μM against human COX-2, and an IC₅₀ of 5 μM against ovine COX-1. Roburic acid reduces the production of inflammatory mediators such as NO and IL-6 in macrophages by inhibiting the NF-κB and MAPK (p38/JNK) pathways. By competitively inhibiting the TNF-TNF-R1 interaction, Roburic acid blocks the downstream NF-κB signaling pathway, thereby inducing cell cycle arrest and apoptosis in cancer cells. Roburic acid specifically inhibits osteoclastogenesis and bone resorption by suppressing the RANKL/TRAF6/NF-κB/NFATc1 axis. Roburic acid can be used in research related to osteolytic diseases such as osteoporosis, colorectal cancer and inflammatory diseases.

Cl-Necrostatin-1 is a RIPK1 inhibitor. Cl-Necrostatin-1 can also inhibit TNF-α-induced necroptosis in Jurkat cells deficient in Fas-associated death domain protein (FADD; EC₅₀ = 180 nM), a modification that prevents caspase activation in response to death-domain receptor signaling. Cl-Necrostatin-1 can also reduce infarct size in a mouse model of middle cerebral artery occlusion (MCAO). Cl-Necrostatin-1 is used for research in cardiovascular and cerebrovascular diseases.

Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) is a mouse-derived IgG2a κ antibody inhibitor that targets mouse 4-1BBL/CD137L.Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) is a chimeric version of the original TKS-1 antibody (HY-P990304). The variable domain sequences are identical to the original TKS-1 but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) reacts with mouse 4-1BB ligand (4-1BBL). Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) can be used for the researches of cancer, infection, inflammation and immunology.

C 87 (Standard) is the analytical standard of C 87 (HY-100735). This product is intended for research and analytical applications. C 87 is a novel small-molecule TNFα inhibitor; potently inhibits TNFα-induced cytotoxicity with an IC50 of 8.73 μM.

Curcumenol (Standard) ((+)-Curcumenol (Standard)) is the analytical standard of Curcumenol (HY-N2259). This product is intended for research and analytical applications. Curcumenol ((+)-Curcumenol) is a natural compound with oral efficacy, exhibiting an IC₅₀ of 12.6 μM and a K_i of 10.8 μM against human CYP3A4. Curcumenol inhibits TNFα-induced phosphorylation/degradation of IκBα, phosphorylation/nuclear translocation of NF-κB p65, as well as the upregulation of MMP3, MMP9, MMP13, TRAF3, IL1RL1, TNFα and IL-1β. Curcumenol suppresses LPS-induced phosphorylation of Akt and p38 MAPK, as well as the production of pro-inflammatory mediators/proteins, and downregulates the SLC7A11/NF-κB/TGF-β pathway. Curcumenol binds to and inhibits the activation of Fyn and Lyn, blocks the function of downstream FcεRI signaling components, and reduces the release of allergic mediators/cytokines. Curcumenol upregulates the expression of KDM6B, and promotes chondrocyte proliferation and cartilage repair. Curcumenol induces ferroptosis and apoptosis, regulates the EMT process, and inhibits tumor growth and metastasis of triple-negative breast cancer. Curcumenol possesses anti-inflammatory, neuroprotective, antioxidant, antitumor, antiviral and hepatoprotective activities. Curcumenol can be used in research related to intervertebral disc degeneration, cancer, inflammation, central nervous system neurodegenerative diseases, allergic reactions and knee osteoarthritis.

AD-35 free base is an orally active, blood-brain barrier-permeable acetylcholinesterase inhibitor with an IC₅₀ of 793 nM. AD-35 free base inhibits metal-induced amyloid-β aggregation and disassembles preformed amyloid-β aggregates. In rat models of cognitive impairment, AD-35 free base attenuates Aβ_25-35-induced astrocyte activation, TNF-α and IL-1β release, inhibits ERK phosphorylation, and alleviates learning and memory deficits. AD-35 free base can be used for research on Alzheimer's disease.

Siegeskaurolic acid is an orally active anti-inflammatory agent. Siegeskaurolic acid inhibits the productions of nitric oxide (NO), prostaglandin E(2) (PGE(2)), tumor necrosis factor-alpha (TNF-alpha) and the activationon of nuclear factor-kappaB .